P
Paul Norwood
Publications - 4
Citations - 1266
Paul Norwood is an academic researcher. The author has contributed to research in topics: Placebo & Type 2 diabetes. The author has an hindex of 3, co-authored 3 publications receiving 1072 citations.
Papers
More filters
Journal ArticleDOI
The Efficacy and Safety of Dermagraft in Improving the Healing of Chronic Diabetic Foot Ulcers: Results of a prospective randomized trial
TL;DR: The results demonstrated that patients with chronic diabetic foot ulcers of >6 weeks duration experienced a significant clinical benefit when treated with Dermagraft versus patients treated with conventional therapy alone.
Journal ArticleDOI
A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers Applicability of a novel insulin-independent treatment
John P.H. Wilding,Paul Norwood,Caroline T'joen,Arnaud Bastien,James F. List,Fred T. Fiedorek +5 more
TL;DR: In patients receiving high insulin doses plus insulin sensitizers who had their baseline insulin reduced by 50%, dapagliflozin decreased A1C, produced better FPG and PPG levels, and lowered weight more than placebo.
Journal ArticleDOI
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
TL;DR: To assess the efficacy and safety of tirzepatide added to insulin glargine in patients with type 2 diabetes with inadequate glycemic control, a Randomized phase 3 clinical trial was conducted at 45 medical research centers and hospitals in 8 countries.
Journal ArticleDOI
Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: A double-blind, randomized, pioglitazone-comparative study
David M. Kendall,Cindy J. Rubin,Pharis Mohideen,Jean Marie Ledeine,Rene Belder,Jorge Luiz Gross,Paul Norwood,Michael O'Mahony,Kenneth N Sall,Greg Sloan,Anthony P. Roberts,Fred T. Fiedorek,Ralph A. DeFronzo +12 more
TL;DR: It was found that 5 mg muraglitazar resulted in greater improvements in A1C and lipid parameters than a submaximal dose of 30 mg pioglitazone when added to metformin.